In contrast, fibroblast growth factor 21 (Fgf21, Log2FC = 1.10) and fibronectin type III domain containing 1 (Fndc1, Log2FC = 2.0), associated with insulin sensitivity and hepatic steatosis, were significantly upregulated after RvE1 treatment (46–49). This evidence concerns the gene INS and fatty liver disease.